Kornimate/medical-research-clean huggingface dataset:
right ventricular contractile reserve in functional tricuspid regurgitation

Conditions: Functional Tricuspid Regurgitation

Summary: aim of the study is to investigate the prognostic value of right ventricular contractile reserve in patients with functional tricuspid regurgitation undergoing tricuspid valve repair or replacement.

chronic volume overload in patients with severe tricuspid regurgitation (tr) leads to right ventricular (rv) dilatation, fibrosis and eventually failure. rv dysfunction is an important determinant of mortality in patients undergoing tricuspid valve surgery. aim of the current study is to investigate the prognostic utility of right ventricular contractile reserve in patients with severe tr undergoing surgical or interventional tricuspid valve repair or tricuspid valve replacement. rv contractile reserve will be assessed using semi-supine bicycle stress echocardiography. echocardiographic parameters are prone to altered loading conditions, such as volume overload. load independent rv contractility can only be measured using invasive pressure-volume-loop (pvl) analysis. therefore rv pvl analysis will be done using conductance catheter in a subset of patients who undergo right heart catheterization for clinical evaluation of pulmonary hypertension. aim of this sub study is the validation of non-invasively derived rv contractile reserve with load independent markers of intrinsic rv contractility.

Eligibility criteria:
inclusion criteria: * severe functional tricuspid regurgitation. * planned surgical or interventional tricuspid valve repair or replacement. * able to cycle on a semisupine tilting exercise table. * informed consent. exclusion criteria: * coronary artery disease with significant ischemia. * unstable angina. * myocardial infarction \<4 month prior to inclusion. * concomitant valvular heart disease (aortic, mitral or pulmonary valve) \> mild-moderate. * constrictive pericarditis. * malignant disease with a life expectancy \< 12 months. * pregnancy. * insufficient image quality on echocardiography.

Keywords: tricuspid regurgitation heart failure right heart stress echocardiography tricuspid repair tricuspid replacement
the prevalence of chronic critical illness in turkey

Conditions: Chronic Critical Illness

Summary: it is known that the number of chronic critical i̇llnes, an iatrogenic condition, increases all over the world. the prevalence of chronic critical illness in turkey is unknown. the investigators aimed to evaluate the etiology, comorbid conditions, demographic data, prevalence, mortality and costs of these patient in intensive care units in turkey. in this multi-centered study, the investigators will retrospectively review the last 1 year of patients receiving treatment at the adult intensive care unit.

the patients who survive an acute critical illness in the intensive care unit (icu) may be delayed in a situation where they are sometimes totally independent before hand due to iatrogenic causes such as infections, dysfunctions, psychological disorders. this can take weeks, sometimes months. this disease is called "chronic critical illness" (cci). most researchers associate cci with the need for prolonged acute mechanical ventilation or the opening of tracheostomy for prolonged acute mechanical ventilation. there is no single condition that does not require an extended mechanical ventilation from cci. in conclusion, cci is characterized by long-term care requiring survival and it is predicted that the cost of these patients will increase with the new patients whose cost will be added in the coming years. in the united states, the number of cci is around 250,000, and this figure has increased by 50-100% in the last 10 years. at least 50% of these patients die in one year and less than 12% recover and become discharged. the annual cost of these patients' health care system is over $ 20 billion. the prevalence of cci in turkey is still unknown. in this study, it was aimed to investigate the prevalence of patients with chronic critical syndrome in intensive care units in turkey.

Eligibility criteria:
inclusion criteria: the patient who is over 18 years old, taking mechanical ventilation support and staying in the critical care unit at least 8 days. additional criterias; clinical diagnosis of following situations: 1. prolonged mechanical ventilation 2. tracheotomia 3. sepsis 4. serious injury (burn) 5. stroke ( hemorhagic or ischemic) 6. traumatic brain injury exclusion criteria: 1. the patients who not having mechanical ventilation support 2. the patient staying less than 8 days in the intensive care unit 3. the patient younger than 18 years old

Keywords: prolonged akut mechanical ventilation tracheotomy
the renin-angiotensin system in essential hypertension

Conditions: Hypertension

Summary: although ace inhibitors and angiotensin receptor blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower bp are still not fully understood. this study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ace inhibitor enalapril and arb candesartan in individuals with mild essential hypertension.


Eligibility criteria:
inclusion criteria: * essential hypertension * sbp 140-159 mmhg * dbp 90-99 mmhg exclusion criteria: * intolerance of or allergy to ace inhibitors or arbs * pregnant or breastfeeding * pre-menopausal women * uncontrolled cardiac or renal failure * diabetes mellitus

Keywords: renin-angiotensin system ace inhibitor angiotensin receptor blocker
comparative study between micro plate fixation and blocking k.wire in management of acute bony mallet finger : randomized controlled clinical trial study

Conditions: Acute Bony Mallet Finger

Summary: mallet finger is an avulsion fracture of the distal phalanx or rupture of the extensor terminal band caused by distal interphalangeal (dip) joint hyperflexion or axial loading. in the treatment of mallet finger fractures, surgical repair is recommended in cases where the fracture involves more than one-third of the distal phalanx joint surface or the distal phalanx becomes volar subluxated the blocking k.wire and micro plate technique are some of the methods used in the treatment of mallet finger fractures in recent years, the blocking k.wire technique has gained popularity owing to its minimally invasive nature and its ability to achieve satisfactory postoperative results the main advantages of micro plate technique include provision of anatomical reduction and stable fixation, avoiding the risk of fragmentation of the small dorsal fragment, allowing early movement and increasing patient comfort and compliance


Eligibility criteria:
inclusion criteria: - acute bony mallet finger involves more than one third of the distal phalanx joint surface or the distal phalanx becomes volar sublaxed exclusion criteria: 1- . crushed distal phalanx 2. soft tissue mallet 3. multiple phalangeal fractures 4. old neglected cases
evaluation of additional treatments for covid-19: a randomized trial in niger

Conditions: Covid-19

Summary: the purpose of this study is to assess whether lopinavir/ritonavir (or eventually other antiviral drugs) is effective at reducing the rate of hospitalization among confirmed covid-19 cases treated as outpatients.

after being informed about the study and potential risks, all patients who meet all eligibility criteria and who give written informed consent will be randomized to receive standard care or standard care plus lopinavir/ritonavir (400mg/100mg twice daily for 14 days). participants will receive daily visits from study staff for 15 days and be followed for a total of 28 days.

Eligibility criteria:
inclusion criteria: * suspect, probable or confirmed case of covid-19 * men and women aged ≥12 years, including pregnant and breastfeeding women * spo2 ≥93% on room air * signature of informed consent form exclusion criteria: * medical indication for hospitalization at the time of enrolment * severe chronic liver disease * known infection with hiv * known allergy or severe intolerance to lopinavir/ritonavir * absolute contra-indication to lopinavir/ritonavir, including concomitant therapy with a medication whose metabolism is dependent on isoform cpy3a with a narrow therapeutic window (e.g., amiodarone, colchicine, simvastatin, lovastatin, etc.) * treatment with an antiviral medication in the 28 days prior to enrolment * dementia or other condition that interferes with active participation in data collection and obtaining informed consent
safety and efficacy of preventative covid vaccines

Conditions: COVID-19 Virus Infection; Vaccine Response

Summary: the stopcov study is a decentralized study comparing covid-19 vaccine specific antibody levels at 24 weeks after final vaccine dose. we plan to study the safety and immunogenicity of covid-19 vaccine(s) in community dwelling persons 70 years and over relative to a younger group (aged 30 - 50 years).

this is a prospective observational study of a cohort of individuals aged 30-50 years and a cohort of individuals aged 70 years and over receiving the covid-19 vaccine. participants will complete a questionnaire to determine eligibility. eligible participants will complete and sign an e-consent and then be provided with a participant id, log in information and password to the database portal, and then be enrolled into the study. participants will complete the study assessments (baseline questionnaire, post vaccine symptom e-diary monthly, check-in questionnaire and dried blood spot specimens)

Eligibility criteria:
inclusion criteria: * must be a resident of ontario arm a: * individuals aged 70 and over * speak, read and understand english (or have a trusted individual to help with study procedures) * will receive a first or second dose of a covid-19 vaccine at an ontario vaccine distribution center. individuals reaching the minimum age requirement by end of the recruitment calendar year are allowed to participate. arm b: * individuals between age 30-50 years * speak, read and understand english (or have a trusted individual to help with study procedures) * receive a first or second dose of a covid-19 vaccine at an ontario vaccine distribution center. exclusion criteria: * not a resident of ontario * individuals who are \< 30 years or those 51-69 years. * those who are unable to complete the study protocols in english either alone or with the assistance of a trusted individual with an electronic device. * participants who do not receive any dose of the vaccine * participants who have already received both doses of the vaccine prior to enrolment.
efficacy and safety of upadacitinib in inflammatory bowel disease

Conditions: Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis

Summary: inflammatory bowel disease (ibd), which encompasses ulcerative colitis (uc) and crohn's disease (cd), has seen significant improvements in patient outcomes with biologic treatments. however, nearly half of the patients are either primary or secondary non-responders to the existing biologics. upadacitinib is the only oral small molecule targeted drug approved for ibd in china. there is a paucity of research on the efficacy and safety of upadacitinib in treating chinese patients with uc and cd, and a lack of study data on the chinese ibd population. this study aims to conduct a multicenter, single-arm, prospective, observational real-world study to analyze the efficacy and safety of upadacitinib in the treatment of chinese patients with ibd, providing a basis for clinical decision-making.


Eligibility criteria:
inclusion criteria: * inclusion criteria were patients of any gender, diagnosed with ulcerative colitis or crohn's disease according to current guidelines, requiring initial upadacitinib treatment as judged by the treating physician, and providing signed informed consent. exclusion criteria: * exclusion criteria included current or planned participation in any other clinical study, contraindications to upadacitinib treatment as per the drug's instructions, and patients deemed unsuitable for the study by the researchers.
the effects of patiromer on serum potassium level and gut microbiome of esrd patients with hyperkalemia

Conditions: ESRD; Hyperkalemia; End Stage Renal Disease

Summary: the effects of patiromer on serum potassium level and gut microbiome of esrd patients with hyperkalemia (potassium greater than 5 milliequivalents per liter) is a non-randomized, crossover study. this is an open-label, pilot clinical trial with 3 sequential phases of (a) 2 weeks of no intervention, (b) 12 weeks of patiromer treatment, and (c) 6 weeks of no intervention. treatment with patiromer will be initiated at a dose of 8.4 grams, once daily and observed for a week, then uptitrated to 16.8 grams once daily. eligible study subjects will collect stool samples and provide blood and urine samples.


Eligibility criteria:
inclusion criteria: * subjects on stable hemodialysis for more than 90 days. * age 18-85 years. * persistent hyperkalemia, defined as elevated serum potassium \> 5.0 meq/l in more than 2 occasions during the previous 3 months. exclusion criteria: * use of pre- or probiotics during the past 2 months * use of antibiotics within the past 2 months, if the patient received a single course of antibiotic. * presence of chronic wound infection and osteomyelitis * inflammatory bowel disease, chronic diarrhea, current c. difficile infection * liver cirrhosis or chronic active hepatitis * treatment with immunosuppressive medications in the past 6 months or more than a week of treatment with prednisone \> 10 mg in the last 3 months * anticipated kidney transplant within 9 months * expected survival \< 9 months * pregnancy, anticipated pregnancy, or breastfeeding * incarceration * participation in another intervention study * severe anemia defined as hemoglobin \< 8.0 g/dl any time during the last 2 months

Keywords: end stage renal disease esrd hyperkalemia
effect of modifications of nutritional intake upon reproductive hormones in normal women

Conditions: Female Reproductive System Disorder

Summary: undernutrition has a known and well recognized negative impact on reproductive hormones, and ultimately fertility. in contrast, much less is known regarding the potential effects of overnutrition on the same hormones. epidemiological data suggest that overnutrition might have a deleterious impact as well on the fertile potential of affected women, but very little is known about the mechanisms implicated. such knowledge may be of importance, given the increasing prevalence of overweight and obesity worldwide.

in the present study, the investigators will perform a very detailed study of the minute to minute regulation of hormones of the neuroendocrine reproductive axis in normal young female volunteers. these studies will initially be performed at base line during isocaloric diet, where the stimulation of lh secretion by exogenous insulin will be tested during hyperinsulinemic eugylcemic clamp studies. the same studies will then be repeated after a period of one month of controlled hypercaloric diet, where volunteers will receive an excess of approximately 30% kcal compared to their calculated daily energy expenditure. it is anticipated that such hypercaloric nutrition will induce a significant decrease in normal insulin sensitivity of these volunteers. thus, the effect of changing whole body insulin sensitivity on the fine regulation of neuroendocrine reproductive hormones will be evaluated.

Eligibility criteria:
inclusion criteria: normally cycling young (between 18 and 30 yo) female, with a bmi between 20 and 25 kg/m2. - exclusion criteria: * personal history of endocrine dysfunction (any kind) * hormonal contraception * pregnancy * food allergy (any kind) * intense physical activity (\>4 hrs/week) * smoking

Keywords: lh pulsatility insulin sensitivity metabolism hypercaloric feeding
assessing clinical trial experiences of patients with osteosarcoma

Conditions: Osteosarcoma

Summary: clinical study participation has historically been heavily biased toward specific demographics. several people will be invited to enroll in this study so that it may collect a variety of data about osteosarcoma clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. people with osteosarcoma who are invited to take part in medical research will benefit from the analysis of the data.


Eligibility criteria:
inclusion criteria: * patient has been diagnosed with osteosarcoma * patient has self-identified as planning to enroll in an interventional clinical trial * patient is a minimum of 18 years or older exclusion criteria: * ecog score of 4 * patient is pregnant * inability to perform regular electronic reporting * patient does not understand, sign, and return consent form

Keywords: osteosarcoma
an investigational immunotherapy study of nivolumab with standard of care therapy vs standard of care therapy for first-line treatment of colorectal cancer that has spread

Conditions: Colorectal Cancer

Summary: this purpose of this study is to evaluate nivolumab (bms-936558) in combination with standard of care (soc) chemotherapy with bevacizumab for the treatment of first-line metastatic colorectal cancer (mcrc).


Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic colorectal cancer, not amenable to curative resection * no prior chemotherapy for metastatic colorectal cancer * ecog performance status of 0-1 * ability to provide adequate tissue sample exclusion criteria: * patients with clinically relevant medical history, including autoimmune disease, cardiovascular disease, hepatic disease or bleeding disorders * prior treatment with an anti-pd-1, anti-pd-l1, anti-pd-l2, or anti-ctla-4 antibody, or any other antibody or drug specifically targeting t-cell co-stimulation or checkpoint pathways * any positive test result for hepatitis b virus or hepatitis c virus indicating presence of virus other protocol-defined inclusion/exclusion criteria apply
emergency/compassionate use - amplatzer duct occluder

Conditions: Patent; Ductus; Arteriosus

Summary: emergency/compassionate use for the amplatzer duct occluder


Eligibility criteria:
inclusion criteria: * emergency/compassionate use for patients not meeting the inclusion crtieria for the amplatzer duct occluder clinical trial
move study in healthy aging people

Conditions: Joint Pain

Summary: bone and muscle losses occur during ageing leading to increased risk of osteoporosis (there are more than 200 million people affected by osteoporosis worldwide), sarcopenia, loss of functionality and mobility. from around 45-50 years onwards, there is a progressive loss of muscle mass and strength (sarcopenia). this is partially due to an impairment of muscle protein synthesis in response to dietary proteins. insufficient dietary protein may contribute to age-related loss of lean body mass (lbm) and strength which ultimately affects body movement. key ingredients in selected investigational product are:milk proteins, calcium, vitamin d, vitamin c, glucosamine sulfate, zinc. they have effects to improve physical mobility and functionality. the investigators expect improved effects of a nutritional intervention combined with a physical activity program on mobility in healthy aging subjects with joint discomfort.


Eligibility criteria:
inclusion criteria: * target 45-65 y old * suffering from (knee) pain. vas on pain assessment \<= 4 on a range 0 to 10 * 20\<bmi\<28 * time since menopause above 2y * ipaq (international physical activity questionnaire) score \<600 exclusion criteria: * oa diagnosed * medicine treatment * chronic pain killers treatment for more than 7 consecutive days with a washout period of 2 weeks between 2 periods of treatment * under corticoid, hormone (adrenal, thyroid) treatment * traditional herbal medicine: in particular with claims on strengthening tendons and bones. this point will be included in ffq (see annex) and evaluate. subjects with chronic tablets supplementation ( calcium or drinking milk over 5 day wk-1 will be excluded, vitamin d, gs, or any with effect on bone and joints ) (set up a ffq to specially investigate intakes of calcium tablets, milk and animal foods) * pregnancy * subject with knee/joint surgery/replacement and cla (cross ligament) injury * history of relevant digestive disease, organic disease of heart, liver or kidney, severe function disorder of liver or kidney, metabolic/endocrine , neurological disease (e.g., parkinson disease, stroke) with residual impairment, vertigo * anaemia * unable to carry out functional tests and questionnaires correctly (koos, physical activity) * lower or upper extremity surgery or fracture in the last 3 months * currently participating or having participated in another clinical trial in the three previous months
botox® economic spasticity trial (best)

Conditions: Muscle Spasticity

Summary: this is a study to investigate if patients who have had a stroke and suffer from spasticity might benefit from being given botox® in addition to the normal standard care. spasticity is characterized by stiffness or frequent cramps accompanied by pain and abnormal movements and can prevent the carrying out of everyday tasks such as walking and getting dressed. botox® is a neurotoxin, which is used to prevent the contraction of muscle fibre and has been shown to reduce spasticity significantly. patients will be enrolled in this study at about 33 locations in europe and canada. study participation will last for about 1 year.


Eligibility criteria:
inclusion criteria: * patients with stroke due to a primary cerebral hemorrhage/infarction * subarachnoid hemorrhage producing an upper motor syndrome affecting one body side which results in a hemi-paralysis/plegia exclusion criteria: * patients with fixed contracture as a result of spasticity in the upper or lower limb planned to be treated and/or patients with other causes of spasticity (e.g. multiple sclerosis, spinal cord injury, etc.)
comparison of deep serratus anterior plane block and combination of deep and superficial serratus anterior plane block

Conditions: Pain, Postoperative; Serratus Anterior Plane Block; Multimodal Analgesia; Thoracic Surgery, Video-Assisted

Summary: video-assisted thoracic surgery (vats) has become a common procedure in thoracic surgery. severe postoperative pain may be encountered in patients undergoing vats. analgesic methods such as thoracic paravertebral block (tpvb), intercostal block, serratus anterior plane block (sapb) and erector spina plane block (espb) are widely used for vats. among these methods, ultrasound (us) guided tpvb is the most preferred method. in recent years, the frequency of application of plane blocks as a component of multimodal analgesia has been increased. espb and sapb are some of them. there are two techniques for sapb application. in deep sapb (dsapb) application, local anesthetic agent is given under the serratus anterior muscle. in the superficial sapb (ssapb) application, the local anesthetic agent is given above the serratus anterior muscle. since it is done by entering from the same point in two applications, it is possible to perform these two applications at the same time with a single needle entry. the mechanisms of regional analgesia techniques used after thoracic surgery operations are also different from each other. therefore, it may be possible to obtain a more effective analgesic effect in patients by combining the mechanism of action of dsapb and ssapb , as in the multimodal analgesia method. this study seeks to evaluate the effect of dsapb and combined dsapb-ssapb pain after vats.


Eligibility criteria:
inclusion criteria: * 18 to 65 years old * asa physical status i-ii-iii * bmi 18 to 30 kg/m2 * elective video assisted thoracoscopic surgery exclusion criteria: * patient refusing the procedure * emergency surgery * chronic opioid or analgesic use

Keywords: serratus anterior plane block, multimodal analgesia, vats